Wave Life Sciences’ siRNA Weight-Loss Drug Shows Strong Early Data

Wave Life Sciences’ investigational obesity therapy WVE-007 has demonstrated encouraging early results in the Phase I INLIGHT trial (NCT06842186). The siRNA-based drug achieved significant, dose-dependent reductions in Activin E, with decreases of 56%, 75%, and 85% observed at 75 mg, 240 mg, and 400 mg doses, respectively. Notably, Activin E suppression in the lowest-dose group lasted six months, supporting the potential for once- or twice-yearly dosing. Biomarker data indicate fat-loss effects comparable to or greater than Novo Nordisk’s Wegovy (semaglutide). The treatment has been well tolerated, with no serious adverse events reported, enabling expansion to a 600 mg cohort. Following the announcement, Wave’s stock rose 9% on October 29, from $7.55 to $8.26, continuing upward the next day. Additional data on body weight and composition are expected between Q4 2025 and Q2 2026, as obesity-drug competition intensifies.

03-11-2025